UBS Group
MRNA icon

UBS Group’s Moderna MRNA Stock Holding History

UBS Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$157M Sell
3,091,826
-1,831,274
-37% -$85.4M 0.02% 744
2025
Q4 		$145M Buy
4,923,100
+1,193,030
+32% +$32.4M 0.02% 753
2025
Q3 		$96.3M Buy
3,730,070
+26,442
+0.7% +$738K 0.02% 1051
2025
Q2 		$102M Buy
3,703,628
+750,700
+25% +$19.8M 0.02% 943
2025
Q1 		$83.7M Buy
2,952,928
+2,334,200
+377% +$82.8M 0.02% 1048
2024
Q4 		$25.7M Buy
618,728
+247,670
+67% +$11.8M ﹤0.01% 2074
2024
Q3 		$24.8M Buy
371,058
+207,858
+127% +$19.1M 0.01% 1654
2024
Q2 		$19.4M Sell
163,200
-52,900
-24% -$6.69M ﹤0.01% 1706
2024
Q1 		$23M Sell
216,100
-330,600
-60% -$33.3M 0.01% 1575
2023
Q4 		$54.4M Buy
546,700
+151,000
+38% +$12.7M 0.02% 933
2023
Q3 		$40.9M Buy
395,700
+155,000
+64% +$17.3M 0.01% 978
2023
Q2 		$29.2M Sell
240,700
-112,636
-32% -$15M 0.01% 1172
2023
Q1 		$54.3M Buy
353,336
+146,700
+71% +$24.2M 0.02% 735
2022
Q4 		$37.1M Buy
206,636
+136,153
+193% +$22.3M 0.01% 993
2022
Q3 		$8.34M Buy
70,483
+40,483
+135% +$6.14M ﹤0.01% 1942
2022
Q2 		$4.29M Sell
30,000
-27,800
-48% -$3.97M ﹤0.01% 2499
2022
Q1 		$9.96M Buy
57,800
+45,800
+382% +$7.71M ﹤0.01% 1944
2021
Q4 		$3.05M Buy
12,000
+2,000
+20% +$585K ﹤0.01% 3343
2021
Q3 		$3.85M Sell
10,000
-2,900
-22% -$1.07M ﹤0.01% 2953
2021
Q2 		$3.03M Hold
12,900
– – ﹤0.01% 3175
2021
Q1 		$1.69M Hold
12,900
– – ﹤0.01% 3742
2020
Q4 		$1.35M Sell
12,900
-7,800
-38% -$789K ﹤0.01% 3766
2020
Q3 		$1.47M Buy
+20,700
New +$1.44M ﹤0.01% 3356
2020
Q2 		– Sell
-14,000
Closed -$419K – 8198
2020
Q1 		$419K Buy
+14,000
New +$322K ﹤0.01% 4128

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's MRNA Position: Q1 2026 in Review

UBS Group increased its Moderna (MRNA) stake by 7.9% in Q1 2026, buying an estimated $15M and bringing the position to 4,407,907 shares worth $224M. The position accounts for 0.03% of the portfolio, ranked #565.

UBS Group first reported a position in MRNA in Q4 2018 and has held it in 30 quarters since. The position peaked at $294M in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • UBS Group held 4,407,907 shares of Moderna worth $224M as of Q1 2026.
  • UBS Group bought 321,141 Moderna shares in Q1 2026, an estimated $15M.
  • Moderna made up 0.03% of UBS Group's portfolio in Q1 2026, its #565 holding.
  • UBS Group first reported a position in Moderna in Q4 2018 and has held it in 30 quarters since.
  • UBS Group's Moderna position peaked at $294M in Q3 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.